Business Insider

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...
Nasdaq

Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
Business Insider

A new migraine medication that's changing the way we treat a condition that affects 38 million Americans just got approved

The FDA just approved a new preventative migraine medication made by drug giant Eli Lilly. The drug, Emgality, is the third in a competitive new class of medication going after the 38 million ...